title: The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120.
abstract: The Thai Phase III clinical trial (RV144) showed modest efficacy in preventing HIV-1 acquisition. Plasma collected from HIV-1-uninfected trial participants completing all injections with ALVAC-HIV (vCP1521) prime and AIDSVAX B/E boost were tested for antibody responses against HIV-1 gp120 envelope (Env). Peptide microarray analysis from six HIV-1 subtypes and group M consensus showed that vaccination induced antibody responses to the second variable (V2) loop of gp120 of multiple subtypes. We further evaluated V2 responses by ELISA and surface plasmon resonance using cyclic (Cyc) and linear V2 loop peptides. Thirty-one of 32 vaccine recipients tested (97%) had antibody responses against Cyc V2 at 2 weeks postimmunization with a reciprocal geometric mean titer (GMT) of 1100 (range: 200-3200). The frequency of detecting plasma V2 antibodies declined to 19% at 28 weeks post-last injection (GMT: 110, range: 100-200). Antibody responses targeted the mid-region of the V2 loop that contains conserved epitopes and has the amino acid sequence KQKVHALFYKLDIVPI (HXB2 Numbering sequence 169-184). Valine at position 172 was critical for antibody binding. The frequency of V3 responses at 2 weeks postimmunization was modest (18/32, 56%) with a GMT of 185 (range: 100-800). In contrast, naturally infected HIV-1 individuals had a lower frequency of antibody responses to V2 (10/20, 50%; p=0.003) and a higher frequency of responses to V3 (19/20, 95%), with GMTs of 400 (range: 100-3200) and 3570 (range: 200-12,800), respectively. RV144 vaccination induced antibodies that targeted a region of the V2 loop that contains conserved epitopes. Early HIV-1 transmission events involve V2 loop interactions, raising the possibility that anti-V2 antibodies in RV144 may have contributed to viral inhibition.
authors.affiliation: Department of Retrovirology, U.S. Army Medical Component, Armed Forces Research Institute of Medical Sciences, USAMC-AFRIMS, Bangkok 10400, Thailand. karasavvan@afrims.org
authors.forename: Nicos
authors.initials: N
authors.lastname: Karasavvas
authors.forename: Erik
authors.initials: E
authors.lastname: Billings
authors.forename: Mangala
authors.initials: M
authors.lastname: Rao
authors.forename: Constance
authors.initials: C
authors.lastname: Williams
authors.forename: Susan
authors.initials: S
authors.lastname: Zolla-Pazner
authors.forename: Robert T
authors.initials: RT
authors.lastname: Bailer
authors.forename: Richard A
authors.initials: RA
authors.lastname: Koup
authors.forename: Sirinan
authors.initials: S
authors.lastname: Madnote
authors.forename: Duangnapa
authors.initials: D
authors.lastname: Arworn
authors.forename: Xiaoying
authors.initials: X
authors.lastname: Shen
authors.forename: Georgia D
authors.initials: GD
authors.lastname: Tomaras
authors.forename: Jeffrey R
authors.initials: JR
authors.lastname: Currier
authors.forename: Mike
authors.initials: M
authors.lastname: Jiang
authors.forename: Craig
authors.initials: C
authors.lastname: Magaret
authors.forename: Charla
authors.initials: C
authors.lastname: Andrews
authors.forename: Raphael
authors.initials: R
authors.lastname: Gottardo
authors.forename: Peter
authors.initials: P
authors.lastname: Gilbert
authors.forename: Timothy J
authors.initials: TJ
authors.lastname: Cardozo
authors.forename: Supachai
authors.initials: S
authors.lastname: Rerks-Ngarm
authors.forename: Sorachai
authors.initials: S
authors.lastname: Nitayaphan
authors.forename: Punnee
authors.initials: P
authors.lastname: Pitisuttithum
authors.forename: Jaranit
authors.initials: J
authors.lastname: Kaewkungwal
authors.forename: Robert
authors.initials: R
authors.lastname: Paris
authors.forename: Kelli
authors.initials: K
authors.lastname: Greene
authors.forename: Hongmei
authors.initials: H
authors.lastname: Gao
authors.forename: Sanjay
authors.initials: S
authors.lastname: Gurunathan
authors.forename: Jim
authors.initials: J
authors.lastname: Tartaglia
authors.forename: Faruk
authors.initials: F
authors.lastname: Sinangil
authors.forename: Bette T
authors.initials: BT
authors.lastname: Korber
authors.forename: David C
authors.initials: DC
authors.lastname: Montefiori
authors.forename: John R
authors.initials: JR
authors.lastname: Mascola
authors.forename: Merlin L
authors.initials: ML
authors.lastname: Robb
authors.forename: Barton F
authors.initials: BF
authors.lastname: Haynes
authors.forename: Viseth
authors.initials: V
authors.lastname: Ngauy
authors.forename: Nelson L
authors.initials: NL
authors.lastname: Michael
authors.forename: Jerome H
authors.initials: JH
authors.lastname: Kim
authors.forename: Mark S
authors.initials: MS
authors.lastname: de Souza
mesh_terms: D016915:AIDS Vaccines / Q000276:immunology*; D000595:Amino Acid Sequence; D002460:Cell Line; D004797:Enzyme-Linked Immunosorbent Assay; D018984:Epitopes, T-Lymphocyte; D005260:Female; D015483:HIV Antibodies / Q000276:immunology*; D015699:HIV Envelope Protein gp120 / Q000276:immunology*; D015658:HIV Infections / Q000276:immunology / Q000517:prevention & control*; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D008297:Male; D008969:Molecular Sequence Data; D040081:Protein Array Analysis
chemical_list: D016915:AIDS Vaccines; D018984:Epitopes, T-Lymphocyte; D015483:HIV Antibodies; D015699:HIV Envelope Protein gp120